Clinical Trial Update: Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the relative bioavailability of two ABT-072 tablet formulations compared with the ABT-072 capsule formulation in Hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-072

Snippet

Sponsor: Abbott | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED